Melsi
Release Forms:
Composition:
- active substance: meloxicam;
- 1 ml contains meloxicam 10 mg;
- 1 bottle (1.5 ml) contains meloxicam 15 mg;
- excipients: meglumine, glycofurol, poloxamer, sodium chloride, glycine, sodium hydroxide, water for injection.
Dosage form. Solution for injection.
Basic physical and chemical properties: transparent yellow or greenish-yellow solution.
1,5 ml per bottle; 5 bottles each in a contoured charunk packaging from a carton.
MELSI is a non-steroidal anti-inflammatory drug (NSAID) of the enolic acid class that has anti-inflammatory, analgesic,
Method of administration and dosage
Dosages.
One injection of 15 mg once a day. Do not exceed 15 mg daily. Treatment should be limited to one injection at the beginning of therapy with a maximum duration of up to 2-3 days in justified exceptional cases (i.e. when other routes of administration are not possible). Adverse reactions can be minimized by using the lowest effective dose for the shortest period of treatment necessary to control symptoms (see section “Peculiarities of use”).
The patient’s need for symptomatic relief and his response to treatment should be periodically assessed.
and antipyretic effects.
Indications
Short-term symptomatic treatment of an acute attack of rheumatoid arthritis and ankylosing spondylitis, when other routes of administration of meloxicam cannot be used.
Contraindications
- III trimester of pregnancy (see section “Use during pregnancy or lactation”);
- the patient’s age up to 18 years;
- hypersensitivity to meloxicam or other constituents of the drug, or to active substances with a similar effect, such as NSAIDs;
- acetylsalicylic acid (meloxicam should not be given to patients who have symptoms of asthma, nasal polyps, angioedema or urticaria after taking acetylsalicylic acid or other NSAIDs);
- gastrointestinal bleeding or perforation associated with previous NSAID therapy in history;
- a history of active or recurrent ulcer/bleeding (two or more separate confirmed cases of ulcer or bleeding);
- severe liver failure;
- severe renal failure without dialysis;
- gastrointestinal bleeding, history of cerebrovascular bleeding, or other bleeding disorders;
- disorders of hemostasis or the simultaneous use of anticoagulants (contraindications associated with the route of use);
- severe heart failure;
- treatment of preoperative pain in coronary artery bypass grafting.
Method of administration and dosage
Dosages.
One injection of 15 mg once a day. Do not exceed 15 mg daily. Treatment should be limited to one injection at the beginning of therapy with a maximum duration of up to 2-3 days in justified exceptional cases (i.e. when other routes of administration are not possible). Adverse reactions can be minimized by using the lowest effective dose for the shortest period of treatment necessary to control symptoms (see section “Peculiarities of use”).
The patient’s need for symptomatic relief and his response to treatment should be periodically assessed.